Humira in a sentence

Naturally, if there is a more effective and safe drug than Humira available for the same indication, then physicians are likely to prescribe it over Humira, or a Humira biosimilar.

Amjevita represents the first biosimilar to the blockbuster drug Humira, kicking off what will likely be a firestorm of clones.

He also believes the deal will help drive adjusted-earnings growth over the next five years, which is crucial considering how Humira biosimilars will likely create a drag on earnings for several years.

Humira has become the best-selling drug in history, with about in all-time global sales.

Its sales peaked last year at $21.2 billion, but its losses could be more than offset by a pair of more recently launched drugs aimed at the same patient groups as Humira.

Management also expects to this year a biosimilar for arthritis treatment, Humira, pending U.S. regulatory approval, to boost revenue.

Management believes these two drugs have the ability to be blockbusters, and they expect the combination of both to surpass peak Humira sales, which is very encouraging for investors.

The company's lead asset - all-time best selling immunology drug Humira - finally loses patent protection this year and sales will enter a period of terminal decline.

The positive, of course, is that it is growing very quickly, at more than 50%, quickly making up for Humira’s decline.

Beginning in 2023, five years after their European counterparts, patients in the United States prescribed the autoimmune disease treatment Humira could finally choose from lower-priced biosimilars.

Based on the drugs, the humira segment is going to have a lucrative growth during the forecast period due to it's a prescription medicine used to reduce the signs and symptoms of ankylosing spondylitis in adults.

Global Humira net revenues of decreased 0.7 percent on a reported basis, or 0.2 percent on an operational basis.

Global Humira net revenues of increased 4.1 percent on a reported basis, or 4.4 percent on an operational basis.

That drug, last year as a treatment for moderate-to-severe plaque psoriasis, is being positioned as a successor to blockbuster AbbVie drug adalimumab (Humira).

You could say that one part of it is the impending Humira patents expiring in 2023.

MarketResearchNest.com adds “Global Humira Market Insights, Forecast to 2025” new report to its research database.

Novartis' generics unit announced the Committee for Medicinal Products for Human Use recommended the full European Medicines Agency approve its Humira biosimilar.